Design: Phase 3, randomised 2:1, open-label with crossover
Population: 236 adults (median age 55) with newly diagnosed Ph-positive ALL
Primary outcome: Event-free survival
Effect: 24-month EFS 86% vs 67% (P<0.001); relapse 5% vs 13%

A GIMEMA phase 3 trial randomised 236 adults with Philadelphia-positive acute lymphoblastic leukaemia, median age 55, two to one to frontline ponatinib plus blinatumomab, a bispecific T-cell engager, or imatinib plus chemotherapy. Control patients with persistent residual disease could cross over.

At two years event-free survival was 86% with ponatinib and blinatumomab against 67% with imatinib and chemotherapy. Relapse was 5% against 13%, and overall survival 90% against 85%. Only about one in five in the intervention group had gone on to stem-cell transplantation.

For a non-haematologist the point is the shift: a leukaemia once treated with intensive chemotherapy and transplant is moving to targeted drugs and immunotherapy, which spares older patients the toxicity of chemotherapy. Follow-up is short, the trial was open-label and crossover will blur any survival comparison. Ponatinib carries a known arterial thrombotic risk, which matters for older patients with vascular disease.

Refer adults with newly diagnosed Ph-positive ALL to a centre offering current targeted and immunotherapy regimens.
Expect fewer of these patients to undergo transplant in first remission.
Watch for arterial thrombotic events in patients on ponatinib, particularly those with vascular risk factors.
Recognise blinatumomab toxicities, including cytokine release and neurological effects, if a patient presents unwell.

Why it matters

It points to a leukaemia treatment that drops intensive chemotherapy without losing control of the disease.

The statistics, in plain English

Event-free survival counts relapse, failure to respond and death. The overall survival difference (90% versus 85%) was smaller and crossover allowed control patients to receive the new regimen, so a survival benefit cannot yet be claimed.